Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Else Nutrition Holdings Inc BABYF


Primary Symbol: T.BABY Alternate Symbol(s):  T.BABY.W.A

Consumer Defensive Packaged Foods
Else Nutrition Holdings Inc is an Israel-based company active in field of food manufacturing. The Company focuses on research, development, manufacturing, marketing and sale of innovative plant-based food and nutrition products and also maintain feeding accessories products to infants and dried food snacks.

Recent & Breaking News (TSX:BABY)

Else Nutrition (TSX:BABY) closes $7.35M public offering

John Ballem  June 29, 2022

Else Nutrition Announces Closing of $7.35 Million Marketed Public Offering Of Units, Including Partial Exercise of Over-Allotment

GlobeNewswire June 29, 2022

ELSE NUTRITION ANNOUNCES SIZE OF PREVIOUSLY ANNOUNCED MARKETED PUBLIC OFFERING OF UNITS

Canada NewsWire June 22, 2022

IIROC Trade Resumption - BABY

Canada NewsWire June 22, 2022

IIROC Trading Halt - BABY

Canada NewsWire June 21, 2022

ELSE NUTRITION ANNOUNCES MARKETED PUBLIC OFFERING OF UNITS

Canada NewsWire June 21, 2022

Else Nutrition (TSX:BABY) signs agreement with buybuy BABY

Shoran Devi June 21, 2022

Else Nutrition Signs an Agreement to Sell Its Products With buybuy BABY, the Leading Specialty Baby Products Retailer in North America

GlobeNewswire June 21, 2022

Else Nutrition to Webcast Live at VirtualInvestorConferences.com June 23rd

GlobeNewswire June 20, 2022

Else Nutrition (TSX:BABY) enters Canada, reaching millions of new potential customers

Jonathon Brown June 13, 2022

Else Nutrition Enters Canada, Reaching Millions of New Potential Customers

GlobeNewswire June 13, 2022

UPDATE - Else Nutrition Enters the Chinese Market, via a Signed Agreement with Baozun, a Leading E-Commerce Distributor in China

GlobeNewswire June 7, 2022

Else Nutrition (TSX:BABY) poised to enter the Chinese market

John Ballem  June 7, 2022

Else Nutrition Enters the Chinese Market, via a Signed Agreement with Baozun, a Leading E-Commerce Distributor in China

GlobeNewswire June 7, 2022

Else (TSX:BABY) completes second preclinical study of its plant-based infant formula

John Ballem  May 31, 2022

Else Successfully Completes Second Preclinical Study on the Path For FDA Approval of World's First Whole Plant, Soy-Free Infant Formula

GlobeNewswire May 31, 2022

Your Answer to the Formula Shortage Crisis

Jonathon Brown May 25, 2022

Leading Edge: Else Nutrition (TSX:BABY)

Trevor Abes  May 24, 2022

Else Nutrition (TSX:BABY) produces world's first whole-plant soy-free infant formula

Trevor Abes  May 24, 2022

Else Produces the World's First and Only Whole Plant, Soy Free Infant Formula in Advance of FDA Approval

GlobeNewswire May 24, 2022